{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:15:25Z","timestamp":1791490525094,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1038\/mt.2016.146","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T07:23:49Z","timestamp":1468308229000},"page":"1602-1614","source":"Crossref","is-referenced-by-count":122,"title":["Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma"],"prefix":"10.1016","volume":"24","author":[{"given":"M Kazim","family":"Panjwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenessa B","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Schutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Gnanandarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Daniel J","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2016.146_bib1","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2016.146_bib2","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1038\/mt.2016.146_bib3","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2016.146_bib4","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2016.146_bib5","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2016.146_bib6","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2016.146_bib7","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1158\/0008-5472.CAN-14-0079","article-title":"Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFN\u03b3","volume":"74","author":"Textor","year":"2014","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.146_bib8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1038\/mt.2016.146_bib9","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2016.146_bib10","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"10.1038\/mt.2016.146_bib11","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","article-title":"Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells","volume":"75","author":"Lo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.146_bib12","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"10.1038\/mt.2016.146_bib13","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"10.1038\/mt.2016.146_bib14","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-11-3890","article-title":"A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor","volume":"72","author":"Urbanska","year":"2012","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.146_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","article-title":"Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo","volume":"1","author":"Lanitis","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1038\/mt.2016.146_bib16","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1038\/mt.2016.146_bib17","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.4049\/jimmunol.1203085","article-title":"Human T cells engineered to express a programmed death 1\/28 costimulatory retargeting molecule display enhanced antitumor activity","volume":"191","author":"Ankri","year":"2013","journal-title":"J Immunol"},{"key":"10.1038\/mt.2016.146_bib18","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1038\/mt.2016.146_bib19","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"10.1038\/mt.2016.146_bib20","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1038\/mt.2016.146_bib21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.146_bib22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1038\/mt.2016.146_bib23","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.146_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"key":"10.1038\/mt.2016.146_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00205629","article-title":"Canine lymphoma-associated antigens defined by murine monoclonal antibodies","volume":"24","author":"Steplewski","year":"1987","journal-title":"Cancer Immunol Immunother"},{"key":"10.1038\/mt.2016.146_bib26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/sj.leu.2404392","article-title":"Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma","volume":"21","author":"Modiano","year":"2007","journal-title":"Leukemia"},{"key":"10.1038\/mt.2016.146_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10577-007-1212-4","article-title":"Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans\u2013man and his best friend share more than companionship","volume":"16","author":"Breen","year":"2008","journal-title":"Chromosome Res"},{"key":"10.1038\/mt.2016.146_bib28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1354\/vp.42-4-468","article-title":"CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma","volume":"42","author":"Jubala","year":"2005","journal-title":"Vet Pathol"},{"key":"10.1038\/mt.2016.146_bib29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/srep00249","article-title":"Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy","volume":"2","author":"O'Connor","year":"2012","journal-title":"Sci Rep"},{"key":"10.1038\/mt.2016.146_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.2017","article-title":"The dog as a possible animal model for human non-Hodgkin lymphoma: a review","volume":"31","author":"Marconato","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1038\/mt.2016.146_bib31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/CJI.0000000000000052","article-title":"Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells","volume":"37","author":"Mata","year":"2014","journal-title":"J Immunother"},{"key":"10.1038\/mt.2016.146_bib32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.vetimm.2014.02.016","article-title":"Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications","volume":"159","author":"Ito","year":"2014","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1038\/mt.2016.146_bib33","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2014.0231","article-title":"Comparative oncology: what dogs and other species can teach us about humans with cancer","volume":"370","author":"Schiffman","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1038\/mt.2016.146_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2013.07.002","article-title":"Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology","volume":"39","author":"Kalos","year":"2013","journal-title":"Immunity"},{"key":"10.1038\/mt.2016.146_bib35","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.bbmt.2006.05.001","article-title":"Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiation","volume":"12","author":"Baron","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1038\/mt.2016.146_bib36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbmt.2006.10.031","article-title":"CD154 blockade and donor-specific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1-Gy total body irradiation","volume":"13","author":"Jochum","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1038\/mt.2016.146_bib37","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3109\/14653249.2011.586997","article-title":"Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation","volume":"13","author":"Chen","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1038\/mt.2016.146_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/TP.0b013e318295c025","article-title":"Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target","volume":"96","author":"Sato","year":"2013","journal-title":"Transplantation"},{"key":"10.1038\/mt.2016.146_bib39","doi-asserted-by":"crossref","first-page":"e98415","DOI":"10.1371\/journal.pone.0098415","article-title":"Expression of PD-L1 on canine tumor cells and enhancement of IFN-\u03b3 production from tumor-infiltrating cells by PD-L1 blockade","volume":"9","author":"Maekawa","year":"2014","journal-title":"PLoS One"},{"key":"10.1038\/mt.2016.146_bib40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1292\/jvms.69.481","article-title":"A novel culture method of canine peripheral blood lymphocytes with concanavalin a and recombinant human interleukin-2 for adoptive immunotherapy","volume":"69","author":"Kato","year":"2007","journal-title":"J Vet Med Sci"},{"key":"10.1038\/mt.2016.146_bib41","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/TP.0b013e31820f07ff","article-title":"Antagonistic and agonistic anti-canine CD28 monoclonal antibodies: tools for allogeneic transplantation","volume":"91","author":"Graves","year":"2011","journal-title":"Transplantation"},{"key":"10.1038\/mt.2016.146_bib42","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.4049\/jimmunol.159.12.5921","article-title":"Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells","volume":"159","author":"Levine","year":"1997","journal-title":"J Immunol"},{"key":"10.1038\/mt.2016.146_bib43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nbt0202-143","article-title":"Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB","volume":"20","author":"Maus","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mt.2016.146_bib44","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/mt.sj.6300134","article-title":"Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules","volume":"15","author":"Suhoski","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.146_bib45","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1182\/blood-2009-05-221135","article-title":"IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation","volume":"114","author":"Bucher","year":"2009","journal-title":"Blood"},{"key":"10.1038\/mt.2016.146_bib46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.vetimm.2012.06.014","article-title":"Canine CD4+CD8+ double positive T cells in peripheral blood have features of activated T cells","volume":"149","author":"Bismarck","year":"2012","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1038\/mt.2016.146_bib47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1172\/JCI110005","article-title":"A unique cell surface antigen identifying lymphoid malignancies of B cell origin","volume":"67","author":"Nadler","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2016.146_bib48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/10428194.2014.914193","article-title":"Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential","volume":"56","author":"Ito","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1038\/mt.2016.146_bib49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"20 Pt 1","key":"10.1038\/mt.2016.146_bib50","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2016.146_bib51","series-title":"The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research: Workshop Summary","author":"National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine, National Academies of Sciences, Engineering, and Medicine","year":"2015"},{"key":"10.1038\/mt.2016.146_bib52","doi-asserted-by":"crossref","first-page":"28911","DOI":"10.18632\/oncotarget.5029","article-title":"Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor","volume":"6","author":"Schutsky","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/mt.2016.146_bib53","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.146_bib54","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood.V98.8.2364","article-title":"Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes","volume":"98","author":"Geiger","year":"2001","journal-title":"Blood"},{"key":"10.1038\/mt.2016.146_bib55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain","volume":"172","author":"Finney","year":"2004","journal-title":"J Immunol"},{"key":"10.1038\/mt.2016.146_bib56","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.146_bib57","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2016.146_bib58","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","article-title":"In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)","volume":"71","author":"Song","year":"2011","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.146_bib59","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1038\/mt.2016.146_bib60","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/sj.gt.3301188","article-title":"Production and concentration of pseudotyped HIV-1-based gene transfer vectors","volume":"7","author":"Reiser","year":"2000","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2016.146_bib61","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4049\/jimmunol.171.1.166","article-title":"CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes","volume":"171","author":"Parry","year":"2003","journal-title":"J Immunol"},{"key":"10.1038\/mt.2016.146_bib62","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1016\/S1525-0016(16)34988-7","article-title":"Chimeric antigen receptor T-cell therapy for companion canines with spontaneous B-cell non-Hodgkin lymphoma","volume":"21","author":"O'Connor","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.146_bib63","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1158\/1078-0432.CCR-10-3310","article-title":"NEMO-binding domain peptide inhibits constitutive NF-\u03baB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma","volume":"17","author":"Gaurnier-Hausser","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616453360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616453360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T01:42:38Z","timestamp":1692409358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616453360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1525001616453360"],"URL":"https:\/\/doi.org\/10.1038\/mt.2016.146","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}